Trippy treatment: Startup synthesizes medicinal ‘shrooms

June 21, 2021 |

In Canada, Core One Labs has developed a process to make psilocybin biosynthetically, opening doors for a more efficient and controlled method of producing the psychedelic for medical purposes. 

Psilocybin, best known as the compound that gives “magic mushrooms” their magic, is being eyed as a medical treatment for depression, anxiety, and addiction. 

Core One Labs says its process can produce psilocybin that is stereochemically identical to the naturally occurring psychedelic and at consistent concentrations. 

 “Core One Labs submitting its patent for its revolutionary biosynthetic psilocybin production system is imminent as we are just days away,” Joel Shacker, CEO of Core One Labs. “This could position the Company as the leader in provision of pharmaceutical API grade psilocybin.” 

Print Friendly, PDF & Email

Tags: ,

Category: Chemicals & Materials

Thank you for visting the Digest.